FIREBRICK PHARMA LIMITED (FRE)

---

AI Coverage Rating: Moderate

ASX AI Signals has generated 1 signal(s) for FRE during the last 90 days, indicating Moderate trading activity

Latest FRE Signals
24/06/2026	SELL
01/04/2026	BUY
27/03/2026	SELL
FRE Share Price
Current Price	$0.037
52 Week High	$0.081
52 Week Low:	$0.030
Trading at (% of 52 Week High)	45.68%

Business Overview

Firebrick Pharma Limited (ASX: FRE) is a pharmaceutical company focused on developing and commercializing innovative treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company aims to advance its drug candidates through clinical trials to address significant unmet medical needs.

ASX Sector Overview

Sector:   Pharmaceuticals, Biotechnology & Life Sciences

The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.

Latest AI Recommendation

The SELL recommendation for FIREBRICK PHARMA LIMITED (FRE) is supported by the low current price indicating potential undervaluation risks and market sentiment trends. However, the confidence is moderated by limited publicly available financial data and potential volatility in the pharmaceutical sector.

Latest  FIREBRICK PHARMA LIMITED(FRE)   News